Danaher Q4 Earnings Beat Estimates, Life Sciences Sales Up Y/Y

Key Takeaways DHR beat Q4 estimates as adjusted EPS hit $2.23 and revenues rose 4.5% year over year.DHR saw broad segment growth, led by Biotechnology revenues up 9% and Diagnostics profit up 14.3%.DHR expects low single-digit core sales growth in Q1 2026 and adjusted EPS of $8.35-$8.50.Danaher Corporation’s (DHR) fourth-quarter 2025 adjusted earnings of $2.23 per share beat the Zacks Consensus Estimate of $2.22. The bottom line increased 4% year over year.Danaher reported net sales of $6.84 billion, which ...